Post Profile






Ribociclib Extends Progression-Free Survival in Pre-Menopausal Patients with Metastatic Hormone Receptor-Positive Breast Cancer

The addition of ribociclib, an inhibitor of the cell cycle, to standard hormone therapy significantly improved progression-free survival (PFS) in pre-menopausal patients with advanced hormone receptor-positive (HR+) breast cancer, according to results of the MONALEESA-7 Phase III clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.
read more

share

Related Posts


Exemestane Plus Everolimus Increased Progression-Free Survival For Women With Metastatic Breast Cancer

Health : Medical News Today

Everolimus in combination with exemestane has shown promise for the treatment of breast cancer. "For postmenopausal patients with hormone receptor (HR)-positive metastatic breast cancer, the addition of everolimus to exemestane mark...

Women With Previously Treated Advanced Breast Cancer Benefit From Addition Of Everolimus To Exemestane

Health : Medical News Today

The mammalian target of rapamycin (mTOR) inhibitor everolimus given with the aromatase inhibitor exemestane markedly boosts progression-free survival (PFS) in post-menopausal women with advanced breast cancer compared with hormonal ...

PARP Inhibitor Improves Progression-Free Survival in Patients with Advanced Breast Cancers and BRCA Mutations

Health : Newswise Medical News

In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over available c...

Ribociclib Improves Progression-Free Survival for Women with Metastatic Breast Cancer

Health : Newswise Medical News

In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, ribociclib, in combination with the aromatase inhibitor letrozole, dramatically improved progression-free survival (PFS) of po...

Ribociclib improves progression-free survival in advanced breast cancer

Health : EurekAlert: Health

(European Society for Medical Oncology) The addition of the CDK4/6 inhibitor ribociclib to letrozole therapy significantly improves progression-free survival in postmenopausal women with hormone receptor-positive advanced breast can...

Comments


Copyright © 2016 Regator, LLC